New Johnson & Johnson data show high booster shot effectiveness

Data from a phase III trial demonstrate a 94-percent protection against Covid-19 with a Johnson & Johnson booster shot.

Photo: Jens Dresling

An additional dose of Johnson & Johnson's Covid-19 vaccine has shown an effectiveness of 94 percent, the company just announced in the published results of a phase III trial.

The vaccine from Johnson & Johnson, which was previously a part of the Danish vaccination program, has demonstrated a single-dose vaccine efficacy of 70 percent.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs